Neurolief, a global leader in medical devices delivering groundbreaking neurotechnology innovations for the treatment of Neurological and Neuropsychiatric disorders, is pleased to announce a strategic equity investment from Sawai Group Holdings Co., Ltd. This investment solidifies the strategic collaboration between Neurolief and the Japanese pharmaceutical corporation which have previously entered into an exclusive agreement for the development and marketing of Neurolief’s Relivion® – a pioneering non-invasive, at-home wearable electroceutical therapy for migraine and depression, in Japan.
Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024
Recommended AI News: Therap Services Enhances its Business Intelligence Module to Improve Performance Assessments
Scott Drees, CEO at Neurolief, expressed his enthusiasm, stating, “We are very pleased to receive this investment from our strategic partner, Sawai Group Holdings, a parent company of Sawai Pharmaceutical Co., Ltd. It not only underscores our shared vision for utilizing Neurolief’s disruptive technology to treat millions of patients suffering from migraine and depression in Japan, but also represents a shared commitment to improving the care of these debilitating chronic diseases.”
Recommended AI News: Conduent Announces Agreement to Sell its Curbside Management and Public Safety Businesses to Modaxo
Mitsuo Sawai, CEO at Sawai Group Holdings, stated, “Guided by our corporate philosophy of ‘Always Putting Patients First,’ we are dedicated to contribution to healthier lives by introducing new and innovative treatment options. With the introduction of Relivion® for at-home treatment under doctor supervision, we are expanding treatment choices for patients suffering from either migraine or depression.”
[To share your insights with us, please write to sghosh@martechseries.com]
